Benznidazole alters the pattern of Cyclophosphamide-induced reactivation in experimental Trypanosoma cruzi-dependent lineage infection.
The factors involved in the reactivation of chronic Chagas disease infection are not clear enough and may be related to host immune unbalance and/or parasite genetic diversity. To evaluate the role of the Trypanosoma cruzi genetic background in the Chagas disease reactivation, we inoculated Cyclophosphamide-immunosupressed (CyI) Swiss mice with clonal stocks from T. cruzi I (Cuica cl1, P209 cl1, Gamba cl1, SP104 cl1), T. cruzi II (IVV cl4, MVB cl8) and T. cruzi (Bug2148 cl1, MN cl2) lineages. We used the parasitemia as the parameter for Chagas disease reactivation and observed that CyI animals infected with T. cruzi stocks showed no reactivation and those infected with T. cruzi II stocks showed only 5% of reactivation. In contrast, immunosuppressed mice infected with stocks from T. cruzi I lineage showed 77.5 and 51.25% reactivation of the infection when Cyclophosphamide treatment was performed 60 and 180 days after inoculation, respectively. Next, we evaluated the efficacy of the Benznidazole (Bz) pre-treatment in reducing or preventing the recurrence of the infection in these CyI animals. In general, the percentage of the parasite recurrence was not altered among the CyI mice that received the Bz pre-treatment during the acute phase of the infection. Interestingly, when pre-Bz treatment was performed during the chronic phase, we observed two different patterns of response: (i) an increased protection among the animals inoculated with the SP104 cl1 (genotype 19) and Cuica cl1 (genotype 20) stocks; (ii) an increased percentage of parasitemia reactivation among mice inoculated with Gamba cl1 (genotype 19) and P209 cl1 (genotype 20) T. cruzi stocks. Our results corroborate our hypothesis by showing that the T. cruzi genetic background in combination with specific Bz treatment has an important role in the Chagas disease reactivation in immunosuppressed animals.
Santos
Daniela M
DM
Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, MG 35400-000, Brazil.
Martins
Tassiane A F
TA
Caldas
Ivo S
IS
Diniz
Lívis F
LF
Machado-Coelho
George L L
GL
Carneiro
Cláudia M
CM
Oliveira
Riva de P
Rde P
Talvani
André
A
Lana
Marta
M
Bahia
Maria T
MT
D000818:Animals; D014355:Chagas Disease / Q000188:drug therapy / Q000469:parasitology / Q000517:prevention & control*; D003520:Cyclophosphamide / Q000494:pharmacology*; D005260:Female; D014644:Genetic Variation; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D009593:Nitroimidazoles / Q000008:administration & dosage / Q000494:pharmacology; D018512:Parasitemia / Q000188:drug therapy / Q000469:parasitology / Q000517:prevention & control; D055502:Secondary Prevention; D016896:Treatment Outcome; D014344:Trypanocidal Agents / Q000008:administration & dosage / Q000494:pharmacology; D014349:Trypanosoma cruzi / Q000187:drug effects / Q000235:genetics / Q000502:physiology
D007166:Immunosuppressive Agents; D009593:Nitroimidazoles; D014344:Trypanocidal Agents; D003520:Cyclophosphamide; C009999:benzonidazole